HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Long-Term Investments (2014 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Long-Term Investments came in at $11.0 million in Q2 2026, up 120.4% year-over-year from $5.0 million in Q2 2025, and up 1.43% quarter-over-quarter from $10.9 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Long-Term Investments (2014 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Long-Term Investments for 13 consecutive years, with $11.0 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Long-Term Investments rose 120.4% year-over-year to $11.0 million in Q2 2026; TTM through Jun 2026 was $11.0 million, a 120.4% increase from a year earlier, with the FY2025 full-year figure at $10.9 million, changed N/A from the prior year.
  • Long-Term Investments was $11.0 million for Q2 2026 at HUTCHMED (China), up from $10.9 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $83.0 million in Q2 2022 and troughed at $130000.0 in Q4 2022.
  • A 5-year average of $32.6 million and a median of $11.0 million in 2026 frame the typical range for Long-Term Investments.
  • Across the five-year window, Long-Term Investments slumped 99.83% in 2022 and jumped 120.4% in 2026, its largest moves.
  • Over 5 years, Long-Term Investments stood at $130000.0 in 2022, then surged by 28930.77% to $37.7 million in 2023, then surged by 113.35% to $80.5 million in 2024, then slumped by 86.51% to $10.9 million in 2025, then grew by 1.43% to $11.0 million in 2026.
  • The last three Long-Term Investments figures came in at $11.0 million (Q2 2026), $10.9 million (Q4 2025), and $5.0 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Amgen 211.50 Bn 197.51 Bn 7.24 Bn -
2 Gilead Sciences 181.29 Bn 178.11 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 5.79 Bn
4 Regeneron Pharmaceuticals 82.55 Bn 74.56 Bn 3.93 Bn 9.83 Bn
5 Argenx Se 61.65 Bn 56.47 Bn 1.37 Bn -4.00 Mn
6 Moderna 54.65 Bn 49.52 Bn 52.00 Mn 1.77 Bn
7 Alnylam Pharmaceuticals 34.18 Bn 30.87 Bn 992.69 Mn 22.17 Mn
8 Biogen 31.36 Bn 30.07 Bn 1.96 Bn -
9 Roivant Sciences 30.01 Bn 30.01 Bn 1.16 Mn -
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - 11.02 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 11.02 Mn
Dec 31, 2025 10.87 Mn
Jun 30, 2025 5.00 Mn
Jun 30, 2024 80.52 Mn
Jun 30, 2023 37.74 Mn
Dec 31, 2022 130,000.00
Jun 30, 2022 83.00 Mn
Dec 31, 2021 76.48 Mn
Jun 30, 2021 118.32 Mn
Mar 31, 2021 133.82 Mn
Dec 31, 2020 139.51 Mn
Jun 30, 2020 106.97 Mn
Dec 31, 2019 98.94 Mn
Sep 30, 2019 145.34 Mn
Jun 30, 2019 146.98 Mn
Mar 31, 2019 158.93 Mn
Dec 31, 2018 -8.00 Mn
Sep 30, 2018 73.65 Mn
Jun 30, 2018 161.59 Mn
Mar 31, 2018 85.86 Mn